Navigation Links
China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
Date:6/2/2009

BEIJING, June 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that China's Vice Premier, Li Keqiang, accompanied with State Councilor and Secretary of the State Council, Ma Kai; Head of General Administration of Quality Supervision, Inspection and Quarantine, Wang Yong; Minister of Ministry of Health, Chen Zhu; Vice Minister of Ministry of Science and Technology, Liu Yanhua; Mayor of City of Beijing, Guo Jinlong; and other delegate members visited Sinovac to inspect its production preparation for a vaccine against influenza A (H1N1). Li Keqiang also emphasized the importance of having a vaccine for influenza A (H1N1) and encouraged Sinovac to step up vaccine production.

At the end of May, the US Center for Disease Control began distributing the influenza A (H1N1) virus strain to manufacturers. Once Sinovac receives the strain, we will commence production immediately.

During the visit, Li Keqiang commented that vaccination plays a crucial role in preventing and controlling infectious diseases. He spoke positively about the country's prevention and control of the disease during the past month, and about the vital role Sinovac has to play in protecting against H1N1. He added that Sinovac is qualified manufacturer to produce influenza A (H1N1) vaccine and will be a very important force for the country in controlling the spread of this virus.

Chen Zhu, Minister of Ministry of Health, commented that Sinovac is a company which has social responsibility.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We were excited to showcase to China's Vice Premier our significant progress towards the production of a vaccine against the influenza A (H1N1) virus. The visit by high-ranking national officials gives us confidence that the Chinese government recognizes our capabilities. We believe that we can play a significant role in providing vaccines against influenza A (H1N1) virus. Once we receive the virus strain, we can begin production immediately."

Sinovac initiated the preparatory activities for influenza A (H1N1) vaccine production at the end of April. In May 2009, Sinovac continued to work closely with various Chinese government authorities and other global health organizations in order to monitor the disease and evaluate strategies to control and prevent its transmission. As a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Sinovac scientists attended the May 19th WHO/UN Meeting with Influenza A (H1N1) Vaccine Manufacturers, which was held in Geneva to update attendees on the global capacity of influenza vaccines and ensure that the vaccines will be available to developing countries.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:  +86-10-8289-0088 x9871
     Fax:  +86-10-6296-6910
     Email: info@sinovac.com

     Investors:
     Amy Glynn/Sara Pellegrino
     The Ruth Group
     Tel:   +1-646-536-7023/7002
     Email: aglynn@theruthgroup.com
            spellegrino@theruthgroup.com

     Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-656-536-7033
     Email: jmccargo@theruthgroup.com

'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
2. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
3. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
4. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
5. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
6. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
7. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
8. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
9. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
10. Sinovac Releases Statement on Healive Vaccine Suspension
11. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... The Blavatnik Family Foundation and the ... of the 2017 Blavatnik Regional Awards for Young Scientists. Established in 2007, ... the New York Academy of Sciences to honor the excellence of outstanding postdoctoral ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
Breaking Biology News(10 mins):